List view / Grid view
There is still much to be done regarding how training is delivered and monitored in core technologies such as flow cytometry. Here, Derek Davies outlines the approaches his team at The Francis Crick Institute are taking to train users of such technologies to ensure quality data is obtained and best…
Having worked in antibody research for over 20 years, Gary McLean has seen how the industry has progressed and understands the potential that antibodies have in the future of medicine. Nikki Withers hears how the focus has shifted from discovery to genetic sequence manipulation and how this can be applied…
Protein therapeutics are a major class of biopharmaceuticals and monoclonal antibodies (mAbs) rule this domain. In this article, Dr Nancy Lopez-Anton outlines the key technologies employed in this important therapeutic discovery area; how they have evolved and what obstacles must be navigated to ensure future success.
As research moves forward at a rapid pace and data is being generated in larger quantities than ever before, one problem the scientific community faces is reproducibility.
Pharmaceutical companies are under increasing pressure to get novel drugs to market as quickly as possible. Here, Sheraz Gul discusses how integrating processes could help streamline drug discovery in the future.
Over three decades, Bio-Rad has built a broad genomics portfolio that touches on nearly every area of life science.
As technology advances and scientific research progresses at a rapid pace, data is being generated in ever-larger quantities. Even with the forward strides in technology and advances in data processing, a common problem widely acknowledged by the scientific community is that of reproducibility. In this article, Matjaz Hren discusses the…
New therapies that direct the immune system to identify and destroy cancer cells, such as CAR-T and immune checkpoint inhibitors, have revolutionised cancer treatment.
Innovations in synthesis technology and gene synthesis have become a powerful and valuable means of obtaining genetic material.
It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.
A significant hurdle in optimising antibody therapeutics is the screening of successive rounds of large libraries of mutant variants in order to recognise the ideal candidate.
The number of oligonucleotide-based platforms on the market is constantly increasing and has led to the emergence of innovative nucleic acid-based therapeutic modalities such as CRISPR-Cas, sgRNAs or mRNAs.
Monoclonal antibodies are used in a wide range of applications, such as basic research, biopharmaceutical development and in vitro diagnostics.
This In-Depth Focus features articles highlighting the importance of effective data management strategies as well as the recent trends in upstream bioprocessing.
The articles in this antibodies In-Depth Focus assess the methods used to develop antibody therapeutics and the evolution of this area of medicine to identify drug targets.
